Extracorporeal shock wave therapy for XXXX : randomised controlled multicentre trial.

@entity1 @entity158 @entity3444
OBJECTIVE: To determine the effectiveness of extracorporeal shock wave therapy compared with placebo in the treatment of @entity3444 . DESIGN: Randomised, blinded, multicentre trial with parallel group design. SETTING: Nine hospitals and one outpatient clinic in Germany. @entity1 : 272 @entity1 with @entity3444 recalcitrant to conservative therapy for at least six months: 135 @entity1 were allocated extracorporeal shock wave therapy and 137 were allocated placebo. MAIN OUTCOME MEASURES: Primary end point was the success rate 12 weeks after intervention based on the Roles and Maudsley score. Secondary end points encompassed subjective @entity158 ratings and walking ability up to a year after the last intervention. RESULTS: The primary end point could be assessed in 94% (n=256) of @entity1 . The success rate 12 weeks after intervention was 34% (n=43) in the extracorporeal shock wave therapy group and 30% (n=39) in the placebo group (95% confidence interval - 8.0% to 15.1%). No difference was found in the secondary end points. Few side effects were reported. CONCLUSIONS: Extracorporeal shock wave therapy is ineffective in the treatment of @entity3444 .
